Newly FDA Approved Alzheimer’s Biomarkers Testing: How to Implement Such Tests in Core Laboratory?
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Newly FDA Approved Alzheimer’s Biomarkers Testing: How to Implement Such Tests in Core Laboratory?
-
Narrated by:
-
By:
About this listen
The diagnostic paradigm for Alzheimer's disease (AD) has rapidly shifted in the last five years as fluid-based biomarker testing has emerged as a reliable, accurate, and accessible means to detect amyloid pathology when evaluating a patient for cognitive decline. This podcast is designed to help pathologists and laboratory professionals gain an understanding of plasma testing for markers such as Abeta40/42, P-tau181, and P-tau217 which are rapidly appearing in the commercial space and how healthcare providers have begun incorporating these tests into routine neurology practice. This podcast will help participants to understand the advantages and limitations of these assays as well as their potential application when a physician is evaluating a patient for AD.